|
|
|
| Physiological and Biochemical Characteristics and Transcriptome Analysis of EBV Infected Jurkat T Cells |
| SHI Rui, CHAI Wenjia, GUI Jingang, et al |
| Beijing Children's Hospital, Capital Medical University, Beijing 100037, China |
|
|
|
|
Abstract Objective: This study aims to investigate the mechanism of EBV infection in T cells by sequencing the transcriptome of EBV-stimulated Jurkat T cells overexpressing CD21. Methods: The target gene CD21 was cloned by PCR and inserted into an overexpression lentiviral vector via molecular cloning techniques, ensuring its stable overexpression on the surface of Jurkat T cells. The CD21-overexpressing Jurkat T cells were then stimulated with EBV(EBV-LV-Jurkat). Transcriptome sequencing was performed on EBV-stimulated CD21-overexpressing Jurkat T cells, untreated Jurkat T cells, and Jurkat T cells infected with lentivirus alone(LV-Jurkat). Gene set enrichment analysis was conducted on differentially expressed genes (DEGs) between EBV-stimulated CD21-overexpressing Jurkat T cells (EBV-LV-Jurkat T) and CD21-overexpressing Jurkat T cells (LV-Jurkat T). Results: GO enrichment analysis of DEGs between EBV-LV-Jurkat T and LV-Jurkat T revealed significant enrichment in the molecular function of MAP kinase tyrosine phosphatase activity , involving the DUSP1, DUSP10, DUSP5, and DUSP8 genes. KEGG pathway enrichment analysis of DEGs indicated that multiple pathways and molecules, similar to those observed in EBV-infected B cells, were significantly enriched in the MAPK, IL-17, HIF-1, NF-κB, and PI3K/AKT signaling pathways, and genes related to the immune response system. Conclusion: This study successfully constructed a model of CD21-overexpressing Jurkat T cells and revealed the impact of EBV stimulation on significantly activating the MAPK signaling pathway, providing crucial preliminary data for further exploration of the mechanism of EBV infection in T cells.
|
|
|
|
|
|
[1] Wong Y,Meehan MT,Burrows SR,et al.Estimating the global burden of Epstein-Barr virus-related cancers [J].Cancer Res Clin Oncol,2022,148(1):31-46.
[2] Damania B,Kenney SC,Raab-Traub N.Epstein-Barr virus:biology and clinical disease[J].Cell,2022,185(20):3652-3670.
[3] Murray PG,Young LS.An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma [J].Blood,2019,134(7):591-596.
[4] Climent F,Nicolae A,Deleval L,et al.Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases:emerging concepts,recent advances,and the putative role of clonal hematopoiesis.A report of the 2022 EA4HP/SH lymphoma workshop[J].Virchows Arch,2023,483(3):333-348.
[5] Molina E,Garcia-Gutierrez L,Junco V,et al.MYC directly transactivates CR2/CD21,the receptor of the Epstein-Barr virus,enhancing the viral infection of Burkitt lymphoma cells [J].Oncogene,2023,42(45):3358-3370.
[6] Rojas-Rechy MH,Gaytan-Morales F,Sanchez-Ponce Y,et al.Herpesvirus screening in childhood hematopoietic transplant reveals high systemic inflammation in episodes of multiple viral detection and an EBV association with elevated IL-1β,IL-8 and graft-versus-host disease [J].Microorganisms,2022,10(8):1685.
[7] Wang J,Liu Y,Zhang Y,et al.Targeting exosomes enveloped EBV-miR-BART1-5p-antagomiRs for NPC therapy through both anti-vasculogenic mimicry and anti-angiogenesis [J].Cancer Med,2023,12(11):12608-12621.
[8] IQbal J,Ansari MA,Kumar B,et al.Histone H2B-IFI16 recognition of nuclear herpesviral genome induces cytoplasmic interferon-β responses [J].PLoS Pathog,2018,12(10):1005967.
[9] Davis AM,Rapley A,Dawson CW,et al.The EBV-encoded oncoprotein,LMP1,recruits and transforms fibroblasts via an ERK-MAPK-dependent mechanism [J].Pathogens,2021,10(8):982.
[10] Tang F,Chen JN,Zhang NN,et al.Expression of CCL21 by EBV-associated gastric carcinoma cells protects CD8+CCR7+ T lymphocytes from apoptosis via the mitochondria-mediated pathway [J].Pathology,2018,50(6):613-621.
[11] Salloum N,Hussein HM,Jammaz R,et al.Epstein-Barr virus DNA modulates regulatory T-cell programming in addition to enhancing interleukin-17A production via Toll-like receptor 9 [J].PLoS One,2018,13(7):200546. |
|
|
|
2024, Vol. 30 
